Page 13 - Read Online
P. 13

Rutledge et al. Hepatoma Res 2019;5:31  I  http://dx.doi.org/10.20517/2394-5079.2019.19                                          Page 7 of 12
























               Figure 4. Rates of recurrent HCC by treatment group and SVR status. Colored bars represent rates of recurrent HCC by SVR status, with
               95%CIs depicted by the capped vertical black lines. Rates of recurrent HCC were as follows: DAA group, overall: 16.76/100py (95%CI:
               10.75, 22.91), SVR: 18.17/100py (95%CI: 3.84, 33.58) and non-SVR: 44.16/100py, (95%CI: 0.006, 90.35). IFN group, overall: 14.31/100py
               (95%CI: 10.17, 19.16), SVR: 11.01/100py (95%CI: 4.85, 17.63), non-SVR: 16.89/100py (95%CI: 10.05, 24.02). Untreated group:
               25.69/100py (95% CI: 14.44,37.27). “Overall” group included some patients not included in SVR or non-SVR groups. SVR: sustained viral
               response; HCC: HCC: hepatocellular carcinoma; CI: confidence interval; IFN: interferon; DAA: direct-acting antiviral




                Study Name
                CO22 HEPATHER
                CO12 CirVir
                Huang et al.
                lkeda et al.1997
                Virgoleux et al.






               Figure 5. Adjusted hazards ratio of risk of recurrent HCC in DAA- vs. IFN-treated populations. The multivariate-adjusted hazard ratio
               of each individual study is represented by the blue square with the size of the square being proportional to the n of the study. The thin
               horizontal grey bars represent the 95%CI of each study and the thick vertical blue line marks where the HR is equal to 1. The red diamond
               with the dashed vertical red line is the overall adjusted HR, which was 0.59 (95%CI: 0.24, 1.03) for recurrent HCC in the DAA population
               compared to the IFN-treated population. IFN: interferon; DAA: direct-acting antiviral; HCC: hepatocellular carcinoma

               14.62/100py, (95%CI: 8.94, 20.52). Again, when we take the second-year rates post-treatment, we saw
               similar recurrence rates [DAA group: 6.66/100py (95%CI: 1.96, 12.11) and IFN group: 5.35/100py, (95%CI:
               0.54, 11.06)]. Our additional meta-analysis of the five studies with multivariate analyses found that the
               unadjusted HR of recurrence in DAA vs. IFN-treated groups was 0.59 (95%CI: 0.11, 1.14) and after adjusting
               for age, gender, baseline AFP, ethnicity and Child-Pugh score, the HR was 0.59 (95%CI: 0.24, 1.03) [Figure 5].


               DISCUSSION
               Our study is the largest meta-analysis to evaluate the risk of HCC after treatment with DAA therapy
               published to date. The results demonstrate that the risk of de novo HCC is similar between IFN- and DAA-
               treated cohorts. In the sub-group analysis by SVR, non-SVR IFN and non-SVR DAA groups had similar
               rates of de novo HCC, although the confidence interval for the DAA cohort was wide because of the very
               small numbers who did not achieve SVR. Those who achieved SVR with IFN had a significantly lower rate
               of HCC occurrence than the DAA-treated SVR group. We postulate that this is because patients who could
   8   9   10   11   12   13   14   15   16   17   18